Abstract-The present study examined the hemodynamic mechanisms of blood pressure (BP) lowering by troglitazone in patients with type 2 diabetes mellitus (DM) at rest and during a mental arithmetic test (MAT). Twenty-two patients with DM with normal to high-normal BP and 12 controls matched for age, gender, glucose tolerance, and BP were studied. DM subjects showed significantly higher systolic BP response during MAT than controls (157 versus 139 mm Hg; PϽ0.01). All 22 DM patients and 5 of 12 controls had systolic BP Ͼ140 mm Hg during MAT. Heart rate and diastolic BP were not significantly different between the 2 groups. The DM group was then randomized to receive troglitazone (nϭ10; 400 mg/d) or glyburide (nϭ12; 20 mg/d). MAT was repeated after 6 months of treatment. Both treatments reduced glucose equally (Ϫ1.7 mmol/L for troglitazone and Ϫ1.5 mmol/L for glyburide), but only troglitazone reduced insulin (Ϫ15 U/mL; PϽ0.001) and C-peptide (Ϫ0.9 ng/mL; PϽ0.02) levels. Troglitazone significantly reduced BP at baseline (PϽ0.05) and systolic BP response to MAT (PϽ0.01), whereas glyburide did not affect BP at baseline or during MAT. Stroke volume and cardiac output did not change with either drug, but troglitazone decreased peripheral vascular resistance (Ϫ112 dyne ⅐ s ⅐ cm Ϫ5 ; PϽ0.05). Improved insulin resistance rather than an improved glycemic control is associated with lower resting and stress BP values in patients with DM. A reduction in vascular resistance may be a primary hemodynamic mechanism of the manner in which troglitazone lowers BP. Insulin sensitizers may offer potential therapeutic advantage in subjects with DM with elevated BP. (Hypertension. 1999;34:83-88.) Key Words: troglitazone Ⅲ blood pressure Ⅲ vasodilation Ⅲ insulin Ⅲ stress, mental E pidemiological studies have reported that diabetic persons have increased prevalence of hypertension, and the San Antonio Heart Study suggests that 85% of diabetics are hypertensive and obese by the fifth decade of their life. [1][2][3] It is also well documented that diabetic patients are prone to develop microvascular and macrovascular disease and have increased mortality. 4 -7 Although it is not clear how years of poor diabetic control lead to elevated blood pressure (BP), normalizing BP in the diabetic population is particularly important to prevent progression of diabetes mellitus (DM)-related complications.Insulin resistance is frequently associated with hypertension, 8 -11 and recent studies have shown that thiazolidinedione derivatives, which are insulin sensitizers, lower BP in diabetic hypertensives 12 and obese subjects. 13 Because this class of drugs improves insulin sensitivity and glycemic control, it is not clear whether the BP-lowering effect is due to glycemic control or to improvement in insulin sensitivity. In addition, recent studies suggest that troglitazone may improve BP by direct actions on the vasculature. Song and colleagues 14 reported that troglitazone inhibits L-type Ca 2ϩ current in rat tail artery and aortic vascular smooth muscle ...